T cell responses to H1N1 and a longitudinal study of seasonal flu vaccination
T cell responses to H1N1 and a longitudinal study of seasonal flu vaccination
批准号:
8306394
负责人:
Mark Morris Davis
金额:
$22.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-18 至 2015-06-30
关键词:
3 year oldAffinityAgeAgingAllelesAnimal ModelAntibodiesAntibody FormationAntigensAttenuatedB-LymphocytesBackBiological AssayBiological MarkersBiostatistics CoreBlood specimenCD4 Positive T LymphocytesCD8B1 geneCell CountCellsCollaborationsCommunicable DiseasesCompetenceCytotoxic T-LymphocytesDataData SetDiseaseDisease OutbreaksDrug FormulationsElderlyEnvironmentEpitopesEuropeanExposure toFailureFire - disastersFoundationsFundingFutureGene ExpressionGenesGenetic IdentityGenomicsGenotypeGoalsGrantHaplotypesHealthHelper-Inducer T-LymphocyteHumanHuman VolunteersHumoral ImmunitiesImmuneImmune responseImmune systemImmunologic MarkersImmunologic MonitoringIndividualInfectionInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza vaccinationInterleukin-17LaboratoriesLearningLifeLongitudinal StudiesMHC Class II GenesMass Spectrum AnalysisMeasuresMethodologyMethodsMonitorPathologyPatternPeptide/MHC ComplexPhenotypePlayProductionReportingRiskRoleSerumSeverity of illnessShapesSorting - Cell MovementSpecificityStagingSurveysSystemSystems BiologyT cell responseT-LymphocyteTechniquesTimeTwin StudiesVaccinatedVaccinationVaccine DesignVaccinesVariantVirusVirus DiseasesWorkbasecell typecohortcombinatorialcytokinegranzyme Bimmune functionimmunogenicityimprovedinfluenza virus vaccineneutralizing antibodynovelnovel markernovel therapeuticspandemic diseasepandemic influenzapathogenrespiratoryresponseseasonal influenzasenescenceswine flutooltrendvaccine efficacyvolunteeryoung adult
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Here we propose to characterize the responses of CD4[+], CD8[+] and gamma-delta T cells to the pandemic influenza H1N1v vaccination or infection in human volunteers. We will use both systems biology approaches as well as analyzing a variety of antigen specific responses with combinatorial peptide-MHC tetramers combined with single cell cytokine analysis, in which we can screen for hundreds of different epitopes and dozens of cytokines. In Aim 1. we will ask whether particular epitope or cytokine expression patterns correlate with a robust vaccine response, as measured by a microneutralization assay, and/or a granzyme B T cell assay, or in the case of infected individuals, disease severity. With the twin studies we will ask how closely does dominant epitope choice follow genetic identity and does that change with increasing age and exposure to infectious diseases. This will be complementary to the results obtained with the complete HLA genotyping being done by the Genomics Core, as we expect that HLA haplotypes will have a major influence on epitope selection and dominance. In Aim 2. we will characterize activation markers and cytokine expression in gamma-delta T cells, which recent evidence suggests influence antibody responses and help shape the responses of CD4[+] and CD8[+] T cells and other immune system components through the early production of IL-17. In Aim 3 we will continue our now three year old longitudinal study of seasonal flu vaccination in young adults (20-30 yrs.) versus older cohorts (60-96 yrs), taking a systems biology approach with the help ofthe Human Immune Monitoring Core and the Biostatistics Core in which we correlate gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind the failure of proper immune function in many older people. We have already identified a number of new markers of immune deficiency, including a decrease in AID expression in B cells and deficient responses to cytokines in many older people using phosphoflow analysis. Support by this mechanism will allow us to look extensively at year-on-year variations and early markers of immune senescence. Lastly, this same systems approach will be taken to compare H1N1v vaccination responses to actual infections, which should help us to understand the similarities and differences between the two and aid in the design of vaccines that are more protective.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Systems biological assessment of T cell responses to vaccination
-
批准号:10584571
-
项目类别:
-
资助金额:$37.9万
-
财政年份:2022
-
负责人:Mark Morris Davis
-
依托单位:
Systems biological assessment of T cell responses to vaccination
-
批准号:10419280
-
项目类别:
-
资助金额:$30.97万
-
财政年份:2022
-
负责人:Mark Morris Davis
-
依托单位:
Administrative Core
-
批准号:10190558
-
项目类别:
-
资助金额:$6.62万
-
财政年份:2021
-
负责人:Mark Morris Davis
-
依托单位:
Molecular interception and immunological characterization of age-associated disease
-
批准号:10190562
-
项目类别:
-
资助金额:$63.87万
-
财政年份:2021
-
负责人:Mark Morris Davis
-
依托单位:
High resolution longitudinal immune monitoring for elucidating immune aging dynamics
-
批准号:10190557
-
项目类别:
-
资助金额:$370.0万
-
财政年份:2021
-
负责人:Mark Morris Davis
-
依托单位:
Administrative Core
-
批准号:10687220
-
项目类别:
-
资助金额:$16.43万
-
财政年份:2021
-
负责人:Mark Morris Davis
-
依托单位:
High resolution longitudinal immune monitoring for elucidating immune aging dynamics
-
批准号:10491673
-
项目类别:
-
资助金额:$350.0万
-
财政年份:2021
-
负责人:Mark Morris Davis
-
依托单位:
Administrative Core
-
批准号:10491674
-
项目类别:
-
资助金额:$14.47万
-
财政年份:2021
-
负责人:Mark Morris Davis
-
依托单位:
High resolution longitudinal immune monitoring for elucidating immune aging dynamics
-
批准号:10687219
-
项目类别:
-
资助金额:$350.0万
-
财政年份:2021
-
负责人:Mark Morris Davis
-
依托单位:
Molecular interception and immunological characterization of age-associated disease
-
批准号:10687228
-
项目类别:
-
资助金额:$74.66万
-
财政年份:2021
-
负责人:Mark Morris Davis
-
依托单位:
Molecular interception and immunological characterization of age-associated disease
-
批准号:10491684
-
项目类别:
-
资助金额:$106.48万
-
财政年份:2021
-
负责人:Mark Morris Davis
-
依托单位:
Project 3: T Cells
-
批准号:10688369
-
项目类别:
-
资助金额:$34.48万
-
财政年份:2020
-
负责人:Mark Morris Davis
-
依托单位:
Influenza responses and repertoire in vaccination, infection and tonsil organoids.
-
批准号:10265695
-
项目类别:
-
资助金额:$175.38万
-
财政年份:2020
-
负责人:Mark Morris Davis
-
依托单位:
Project 3: T Cells
-
批准号:10222107
-
项目类别:
-
资助金额:$93.92万
-
财政年份:2020
-
负责人:Mark Morris Davis
-
依托单位:
Administrative and Clinical Core
-
批准号:8306399
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2011
-
负责人:Mark Morris Davis
-
依托单位:
Pilot Projects Core
-
批准号:8306400
-
项目类别:
-
资助金额:$9.72万
-
财政年份:2011
-
负责人:Mark Morris Davis
-
依托单位:
Vaccination and infection: indicators of immunological health and responsiveness
-
批准号:8303264
-
项目类别:
-
资助金额:$308.75万
-
财政年份:2010
-
负责人:Mark Morris Davis
-
依托单位:
Vaccination and infection: indicators of immunological health and responsiveness
-
批准号:8509587
-
项目类别:
-
资助金额:$290.88万
-
财政年份:2010
-
负责人:Mark Morris Davis
-
依托单位:
Vaccination and infection: indicators of immunological health and responsiveness
-
批准号:7978139
-
项目类别:
-
资助金额:$457.98万
-
财政年份:2010
-
负责人:Mark Morris Davis
-
依托单位:
Vaccination and infection: indicators of immunological health and responsiveness
-
批准号:8119166
-
项目类别:
-
资助金额:$327.18万
-
财政年份:2010
-
负责人:Mark Morris Davis
-
依托单位:
海外基金